Sotatercept for Pulmonary Arterial Hypertension Patients

By Danélia Botes

January 25, 2024

A New Ray of Hope

Pulmonary arterial hypertension (PAH) is a rare, progressive disease characterised by the thickening of pulmonary artery walls, causing increased resistance and pressure that makes it difficult for the heart to pump blood to the lungs. This leads to symptoms such as shortness of breath, fatigue, chest pain, and dizziness and can result in right ventricle dysfunction and premature death. This article explores the Final Evidence Report assessing the comparative clinical effectiveness and value of sotatercept from The Institute for Clinical and Economic Review (ICER).

Understanding PAH:

PAH significantly impacts patients financially, with costs exceeding $100,000 per person annually. The disease affects 50,000 to 100,000 people in the US, typically between the ages of 30 and 60, and is more common in women. PAH can be idiopathic, inherited, or associated with exposure to certain substances or conditions. The disease severely impacts the quality of life, particularly in physical function domains. One-fifth of PAH patients die within three years after diagnosis, significantly reducing lifespan. 

Current PAH Treatment Landscape:

Current treatment for PAH includes medications that promote vasodilation with the goals of improving functional status and survival. However, these treatments can be burdensome, and often have to be used in multiple combination therapies. Despite treatment many cases will inevitably be referred for lung or heart-lung transplantation.

Sotatercept for PAH treatment:

Sotatercept (Merck & Co., Inc) is a first-in-class activin signaling inhibitor and potentially disease-modifying drug. It is administered as a subcutaneous injection every three weeks and has been shown to improve pulmonary blood flow. The US Food and Drug Administration (FDA) has received a request for sotatercept, with a decision anticipated by March 26, 2024.

The STELLAR Trial:

The pivotal trial for sotatercept was STELLAR, a Phase III randomised, placebo-controlled trial based on 323 cases of PAH. The results showed that treatment with sotatercept added to background therapy can improve clinical outcomes for patients with PAH. The risk of clinical deterioration or death dropped 84%. Side effects of sotatercept included a considerable increase in telangiectasias, haemoglobin levels, and bleeding.

Economic impact:

The exact cost of sotatercept is still unknown. However, it is estimated that, if priced within the health benefit pricing benchmark (HBPB) range, all suitable patients could be treated with sotatercept over a five-year period without causing significant budget issues. ICER used a de novo decision analytic model to analyse the cost-effectiveness of adding sotatercept to background therapy in the health care sector. Sotatercept treatment led to increased symptom-free time at rest, quality-adjusted life years, and equal value life years. HBPB for sotatercept ranges from $17,900 to $35,400 annually as per the report.

Reference url

Recent Posts

South African National Health Insurance Bill
          

High Court on South African National Health Insurance Bill

📢Latest update on the NHI! 📢 Dive into our latest piece on the judicial review of the South African National Health Insurance Bill. Learn about the intriguing case and its implications on the healthcare industry. 🏛️💼💡 #HealthcarePolicy #LegalReview #NationalHealthInsuranceBill

Global Perspective on Orphan Medicines
                

A Global Perspective on Orphan Medicines and Rare Diseases

Discover the global perspective on orphan medicines and their role in treating rare diseases. Learn about the unique challenges and incentives in their development. 🌍💊 #OrphanMedicines #RareDiseases #HealthcareInnovation #RareDiseaseDay. Read more here

            

The Impact of Universal Health Coverage on Poverty Reduction in Low and Middle-Income Countries

📚 New research findings alert! 🚨 A recent study shows that increasing coverage of maternal, child and inpatient services is associated with reduced poverty in low and middle-income countries. 💡 This supports pro-poor approaches towards Universal Health Coverage. 🌍 Let’s work together to ensure #HealthForAll and #EndPoverty. Read more here 📖 #UHC #GlobalHealth #HealthEquity

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER




SERVICES

© 2024 Syenza™. All rights reserved.